StemCell Institute Inc. (TYO:7096)
Japan · Delayed Price · Currency is JPY 781.00
+1.00 (0.13%)
Dec 15, 2025, 3:01 PM JST
StemCell Institute Revenue
StemCell Institute had revenue of 715.00M JPY in the quarter ending September 30, 2025, with 2.88% growth. This brings the company's revenue in the last twelve months to 2.72B, up 3.03% year-over-year. In the fiscal year ending March 31, 2025, StemCell Institute had annual revenue of 2.68B with 7.98% growth.
Revenue (ttm)
2.72B
Revenue Growth
+3.03%
P/S Ratio
2.94
Revenue / Employee
23.26M
Employees
117
Market Cap
7.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 2.68B | 198.00M | 7.98% |
| Mar 31, 2024 | 2.48B | 390.00M | 18.65% |
| Mar 31, 2023 | 2.09B | 310.00M | 17.41% |
| Mar 31, 2022 | 1.78B | 372.00M | 26.40% |
| Mar 31, 2021 | 1.41B | -267.00M | -15.93% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.42T |
| Otsuka Holdings | 2.42T |
| Astellas Pharma | 2.01T |
| Daiichi Sankyo Company | 1.98T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.06T |
| Olympus | 977.65B |
| HOYA Corporation | 892.50B |